FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) had its "market perform" rating re-affirmed by analysts at William Blair.
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.